Oxford center aims to increase clinical trial success rate

05/7/2013 | Bloomberg · PharmaTimes (U.K.)

A new research center at the University of Oxford aims to reduce the midstage clinical trial failure rate, which stands at about 90%. Hong Kong billionaire Li Ka-Shing and the U.K. government donated about $31 million each to fund the Li Ka-Shing Centre for Health Information and Discovery, with the goal of using data from patient records, genomic sequencing, clinical trials and national registries to help doctors make better decisions. Drugmakers Eli Lilly & Co., GlaxoSmithKline, Pfizer, Johnson & Johnson, Boehringer Ingelheim, Novartis, AbbVie and Takeda are giving $8 million each to the Target Discovery Institute at Oxford in an effort to find innovative targets for drug development.

View Full Article in:

Bloomberg · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC